A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR: VESIcare In Combination With Tamsulosin in OAB Residual Symptoms.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR: VESIcare In Combination With Tamsulosin in OAB Residual Symptoms.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Solifenacin (Primary) ; Tamsulosin
  • Indications Overactive bladder; Urge incontinence
  • Focus Therapeutic Use
  • Acronyms VICTOR
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 14 Feb 2008 The expected completion date for this trial is now 1 Jan 2007.
    • 30 Jan 2008 Status changed from in progress to completed according to NCT.
    • 14 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top